Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Slides:

Advertisements

Similar presentations

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

Advertisements

Prostate Cancer 2008: Challenges in Diagnosis and Management

Renal Cell Carcinoma: Prognostic Factors and Patient Selection

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Bladder Cancer: Management and Future Directions

Hormone Therapy for Prostate Cancer: Exploring Current Controversies

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Martin C. Michel European Urology Supplements

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Bladder Cancer: A Major Public Health Issue

Towards Early and More Specific Diagnosis of Prostate Cancer

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Prostate Cancer Management: What Does the Future Hold?

A Novel Treatment of Premature Ejaculation

Localised and Locally Advanced Prostate Cancer: Who to Treat and How?

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Luis Martínez-Piñeiro European Urology Supplements

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Risk Factors for the Development of Bone Metastases in Prostate Cancer

Volume 55, Issue 3, Pages (March 2009)

Optimising Hormone Therapy in Advanced Disease

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Antonio Alcaraz, Pierre Teillac European Urology Supplements

What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Jacques Irani European Urology Supplements

Neal Shore European Urology Supplements

Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

PSA Levels and the Probability of Prostate Cancer on Biopsy

Nicholas D. James, Jim W. Growcott European Urology Supplements

The Hallmarks of BPH Progression and Risk Factors

Sergio Bracarda European Urology Supplements

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Preclinical Profile of Zoledronic Acid in Prostate Cancer Models

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Prostate Cancer 2008: Challenges in Diagnosis and Management

Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer P. Mongiat-Artus, P. Teillac

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Richard Berges European Urology Supplements

Axel Heidenreich European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

Profile of Silodosin European Urology Supplements

Bob Djavan European Urology Supplements

Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid Theresa A. Guise,

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Highlighting Unmet Needs: Real Patients, Difficult Choices

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Testim® Gel: Review of Clinical Data

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

C.G Roehrborn, T McNicholas European Urology Supplements

Beyond Skeletal-Related Events

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Emmanuel Chartier-Kastler, Andrea Tubaro European Urology Supplements

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Axel Heidenreich European Urology Supplements

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Michael Marberger European Urology Supplements

Introduction European Urology Supplements

Presentation transcript:

Challenges and Opportunities in Hormone-Resistant Prostate Cancer Kurt Miller European Urology Supplements Volume 8, Issue 1, Pages 36-45 (January 2009) DOI: 10.1016/j.eursup.2008.10.006 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Overall survival in the TAX 327 study. Adapted from Berthold et al [5]. Reprinted with permission from American Society of Clinical Oncology. © 2008 All rights reserved. European Urology Supplements 2009 8, 36-45DOI: (10.1016/j.eursup.2008.10.006) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Overall survival and prostate-specific antigen (PSA) response in the Androgen-Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere (ASCENT) phase 2 trial. Adapted from Beer et al [7]. Reprinted with permission from American Society of Clinical Oncology. © 2008 All rights reserved. European Urology Supplements 2009 8, 36-45DOI: (10.1016/j.eursup.2008.10.006) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 Overall survival with ZD4054 10mg or 15mg versus placebo. Adapted from James et al [30]. Reprinted with permission from Elsevier. European Urology Supplements 2009 8, 36-45DOI: (10.1016/j.eursup.2008.10.006) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 4 The ZD4054 ENdoTHelin A USE (ENTHUSE) phase 3 clinical trials programme. European Urology Supplements 2009 8, 36-45DOI: (10.1016/j.eursup.2008.10.006) Copyright © 2008 European Association of Urology Terms and Conditions